Mr. Sean Doyle:

The ambition to progress a testing solution for the United States of America came about last week. It is very early days. I know the DAA were talking about some solutions for the North American market that should be evaluated. We are keen to urge that we act with speed and that we make sure there is tight co-ordination across all stakeholders. There are many issues to deal with, including the validation, the data, the transfer of data and the standards of operation relative to the standards set by the health authorities in either jurisdiction. There is a lot of work to do. It needs to be done quickly and executed in a very co-ordinated and joined up way. Considering Ireland's importance to the US market and the importance of foreign direct investment and tourism to the Irish economy, it should be a priority for us as a group of stakeholders to work on. It is early stages of engagement but we are very keen to move on it, and we would bring a lot of energy to supporting it.